For Novo Nordisk’s management, it is something of a predicament that it is now in the process of making more redundancies just a few months after the pharmaceutical company carried out a historically large round of layoffs in the fall, according to Kasper Meisner Nielsen, professor and head of the Center for Corporate Governance at Copenhagen Business School (CBS).
